Disease relevance of Gram-Positive Bacterial Infections

• Spontaneous peritonitis and systemic lupus erythematosus. Importance of accurate diagnosis of gram-positive bacterial infections [1].
• The present study examined the efficacy of teicoplanin, a glycopeptide antibiotic active against gram-positive bacterial infections in various animal models, in the treatment of experimental endocarditis due to a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin [2].
• Palmitoleic acid may be useful in topical formulations for treatment of secondary gram-positive bacterial infections, as a gram-positive bacteria antimicrobial in wound dressings, and as a natural gram-positive antimicrobial preservative in skin and hair care products [3].
• In clinical trials involving hospitalized patients with skin/soft tissue infections, community-acquired pneumonia and serious Gram-positive bacterial infections, linezolid appeared to be an effective treatment option, comparable in efficacy to vancomycin [4].

High impact information on Gram-Positive Bacterial Infections

• Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections [5].
• Interestingly, four of these genes are also required for Toll activation by fungi, while one is specifically associated with signaling in response to gram-positive bacterial infections [6].
• In vivo RNA interference analysis reveals an unexpected role for GNBP1 in the defense against Gram-positive bacterial infection in Drosophila adults [7].
• Our results reveal that MKP-1 critically regulates the expression of TNF-alpha and interleukin-1 beta in RAW264.7 cells and further suggest a central role for this phosphatase in controlling the inflammatory responses of primary macrophages to Gram-positive bacterial infection [8].
• Fusidic acid (FA) is a steroid antibiotic commonly used against Gram positive bacterial infections [9].

Chemical compound and disease context of Gram-Positive Bacterial Infections

• We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci [10].
• Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [11].
• Erythromycin, first introduced for clinical use 30 years ago, was found to be effective for the treatment of gram-positive bacterial infections [12].
• BMY-28100 was about twice as active as cefaclor against three Gram-positive bacterial infections [13].
• MDL 19,592 is a new semisynthetic cephalosporin with a good therapeutic potential against Gram-positive bacterial infections when administered orally or parenterally [14].

Gene context of Gram-Positive Bacterial Infections

• These findings suggest that monocytic cells respond to Gram-positive bacterial infection by the production of CCL18/PARC in the synovial cavity [15].
• Moreover the respective cytokine concentrations were significantly higher in the gram-negative/LPS-positive compared to the gram-positive bacterial infections (P<0.01) [16].

Analytical, diagnostic and therapeutic context of Gram-Positive Bacterial Infections

• Some strains of methicillin-resistant S. aureus and methicillin-resistant S. epidermidis demonstrated very low levels of minimum inhibitory concentration for moxifloxacin, suggesting the potential application of the drug to treat some drug-resistant gram-positive bacterial infections [17].

References